Notice

JIN-A02, A Novel 4th Generation EGFR TKI selected for the European Thoracic Oncology Platform - A First for Korean Pharma.

SEOUL, South Korea, Aug. 11, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGF 2022.08.12

Notice

Prof. Cho, head of the lung cancer center at Yonsei Cancer Hospital, "J INTS BIO's new oral administration 4th generation EGFR TKI 'JIN-A02' expected to be a game changer"

SEOUL, South Korea, June 21, 2022 /PRNewswire/ -- Prof. Cho Byoung-chul at Yonsei University College of Medicine (Director, Lung Cancer Center, Yonsei 2022.06.22

Notice

J INTS BIO successfully held two Korean Advisory Board Meetings for its Novel Oral 4th Generation EGFR TKI (JIN-A02)

Members include the 10 leading NSCLC experts in Korea, discussing clinical design and R&D…SEOUL, South Korea, June 10, 2022 /PRNewswire/ -- J INTS BIO 2022.06.10

Notice

J INTS BIO 4th Generation EGFR TKI (JIN-A02) US FDA Phase 1/2 IND submission completed

SEOUL, South Korea, June 3, 2022 /PRNewswire/ -- J INTS BIO, a company specializing in the development of novel anticancer and orphan drugs, announced 2022.06.03

Notice

Contact Us

Thank you for your interest in learning more about Joseah Bio.We care about your questions and concerns.Please kindly contact us by email below if you 2020.01.17

Notice

Welcome

We are setup and based in Seoul, South Korea in March 2020.At Joseah, we want to be the chrysalis and a positive force in bringing life changing and h 2020.01.13